The Congolese National Medicines Regulatory Authority (DPM) with WHO to guarantee the development and circulation of safe and effective drugs, by implementing the Global Benchmarking Tool (GBT)

Home / Healthcare and public health research / The Congolese National Medicines Regulatory Authority (DPM) with WHO to guarantee the development and circulation of safe and effective drugs, by implementing the Global Benchmarking Tool (GBT)

The Congolese National Medicines Regulatory Authority (DPM) with WHO to guarantee the development and circulation of safe and effective drugs, by implementing the Global Benchmarking Tool (GBT)

March 10, 2021 Dario Scaramuzzi 0 Comments 10 tags

As part of the strengthening of health systems and in particular the regulation of drugs and health products within the Africlinique project, the headquarters of the World Health Organization (WHO), the WHO Regional Office for Africa (AFRO), and the WHO Country Office (PO) in the Republic of Congo provided technical assistance to support the Directorate of Pharmacy and Medicine (DPM) of Congo from February 15 to 19 2021 in Brazzaville (Republic of Congo).

The Global Benchmarking Tool (GBT) integrates the Maturity Level (ML) of the various drug regulatory functions in a computerized platform that facilitates its use and the ranking of maturity indicators. This self-assessment has enabled several countries in the sub-region to identify their ML as well as to put in place institutional development plans (IDPs) in order to access a ML which guarantees safety, quality and effectiveness of drugs in development and in circulation.

Click here to for news release in English.

Explore More

Ebola outbreak in Republic Democratic of the Congo: switching from MEURI (Monitored Emergency Use of Unregistered and Investigational Interventions) to a RCT (Randomized Clinical Trial) for 4 experimental medications in the treatment of Ebola Virus Disease

An international research team has begun patient enrollment in a clinical trial testing multiple investigational Ebola therapies in the Democratic Republic of the Congo (DRC). The randomized, controlled trial is

In a Controlled Human Infection Model (CHIM) study, a well-characterised strain of an infectious agent is given to carefully selected adult volunteers in order to better understand human diseases, how they spread, and

Ebola vaccine candidates are currently being evaluated in phase I–III clinical trials conducted in Africa, the EU and the US. Although preclinical development of candidate vaccines utilise different platforms, including

The Congolese National Medicines Regulatory Authority (DPM) with WHO to guarantee the development and circulation of safe and effective drugs, by implementing the Global Benchmarking Tool (GBT)

Leave a Reply Cancel reply

Explore More

Ebola outbreak in Republic Democratic of the Congo: switching from MEURI (Monitored Emergency Use of Unregistered and Investigational Interventions) to a RCT (Randomized Clinical Trial) for 4 experimental medications in the treatment of Ebola Virus Disease

Controlled Human Infection Model (CHIM) studies

Ebola vaccines at a la glance